Navigation Links
Researchers develop device that simulates gastro-intestinal tract
Date:3/31/2014

A breakthrough in drug testing developed by a University of Huddersfield lecturer could lead to cheaper, more effective medicines. Dr Hamid Merchant is a member of the team that has created a device which accurately simulates the gastro-intestinal tract and how it absorbs medication. This means that the cost of clinical trials could be greatly reduced, with savings passed on to customers.

Dr Merchant has joined the University as a Senior Lecturer in Pharmaceutics. Previously a postdoctoral fellow at University College London (UCL), he has extensive research experience, with a speciality in drug delivery and formulations. He has published regularly in peer-reviewed journals and made presentations to prestigious bodies that include the American Association of Pharmaceutical Scientists, to whom he has described his work in developing the apparatus for testing the solubility of medicines in their annual meeting and exposition in November 2013 at St Antonio (Links to abstracts... AAPS 2013-R6065, AAPS 2013-T3050, AAPS 2013-W5338, AAPS 2013-T3119, AAPS 2013-R6310).

The device is the subject of a patent application with potential commercial partners already expressing interest and a working prototype has been constructed at UCL. It has already been used, under contract, by drug companies in order to test new products. Dr Merchant now aims to establish a second prototype at the University of Huddersfield.

Dr Merchant explained that the cycle for developing and delivering a new drug involves pre-clinical tests on animals. If these are deemed safe and satisfactory, clinical trials on humans can then begin. But differences between animal and human gastrointestinal tracts mean that the pre-clinical tests do not always provide sufficiently reliable information about drug absorption from differing formulations. This has to be investigated at considerable expense during the clinical trial phase.

Therefore, Dr Merchant and his colleagues developed a laboratory device that simulates the human gut and its differing pH gradients, which play a decisive role in determining the manner, in which orally-administered medications are dissolved and then absorbed. It is now possible to fairly discriminate the formulations of a new drug and identify potential candidates for further development that are likely to be successful during clinical trials.

"By minimising human trials we would reduce the cost of development, which is then charged to patients when the drug comes to the market if the development costs are lower, then we can make new drugs more affordable," said Dr Merchant, who has research experience in industry as well as academia.

The testing device, co-developed by Dr Merchant, includes a chamber for holding a solvent medium plus a pH probe and a control unit. This monitors changes in the pH of the solvent medium in order to test the performance of a drug carrier at different levels of acidity or alkalinity, mimicking the conditions of the gastrointestinal tract. The device is particularly suitable for testing and developing dosage forms for oral delivery of drugs and can also simulate the variability between individuals.


'/>"/>

Contact: Nicola Werritt
nicola.werritt@hud.ac.uk
01-484-473-315
University of Huddersfield
Source:Eurekalert  

Related medicine news :

1. UNC researchers show cancer chemotherapy accelerates molecular aging
2. NUS researchers developed worlds first fluorescent sensor to detect date rape drug
3. Cancer researchers find key protein link
4. Researchers: Biomarkers predict effectiveness of radiation treatments for cancer
5. Researchers issue state-of-the-state on genetic-based testing and treatment for breast cancer
6. Researchers identify impaired new learning in persons with Parkinsons disease
7. Researchers identify potential new therapeutic target for controlling high blood sugar
8. Ottawa researchers find new pathway connected to type 2 diabetes
9. Shoulder revision repair surgery not as successful 2 years later, say researchers
10. Researchers find significant increase in painkillers prescribed to US adults in the ER
11. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers develop device that simulates gastro-intestinal tract
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the director ... transitioned to chief of the Division of Plastic Surgery at what is now known ... began a second three-year term in January of 2016. , The original selection was ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... ... 05, 2016 , ... Health and wellness is a topic that should concern ... they are experiencing an illness. Migraines are a severe form of a headache and ... would not wish the pain on their worst enemy, the feeling can last for ...
(Date:2/5/2016)... ... 05, 2016 , ... –This week, Atascadero water heater company First Call ... heater. To view the report, click here or see below. , ... their pros and cons, the type chosen is almost entirely up to personal preference. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Frontier Pharma: ... Commercializing First-in-Class Innovation Chronic Obstructive ... with chronic inflammation of the airways and lungs. ... symptoms make the disease one of the leading ... death in the world. COPD is linked to ...
(Date:2/4/2016)... COLUMBUS, Ohio, Feb. 4, 2016 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year.  Reported sales ... in the quarter. , Net earnings per diluted ... in the prior- year period.  Adjusted EPS was $4.65, ...
(Date:2/4/2016)... 4, 2016 In response to the opioid abuse ... Commissioner for Medical Products and Tobacco, along with other FDA ... agency,s approach to opioid medications. The plan will focus on ... in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure that ...
Breaking Medicine Technology: